Nuklearmedizin 1977; 16(01): 36-41
DOI: 10.1055/s-0037-1620604
Originalarbeiten – Original Articles
Schattauer GmbH

Basic Studies of Various 99mTc-Labelled Renal Agents and Clinical Application of 99mTc-Malate

Authors

  • T. Machida

    1   From the Department of Urology, The Jikei University, School of Medicine and Dainabot Radioisotope Laboratories, Tokyo
  • M. Miki

    1   From the Department of Urology, The Jikei University, School of Medicine and Dainabot Radioisotope Laboratories, Tokyo
  • M. Ueda

    1   From the Department of Urology, The Jikei University, School of Medicine and Dainabot Radioisotope Laboratories, Tokyo
  • A. Tanaka

    1   From the Department of Urology, The Jikei University, School of Medicine and Dainabot Radioisotope Laboratories, Tokyo
  • I. Ikeda

    1   From the Department of Urology, The Jikei University, School of Medicine and Dainabot Radioisotope Laboratories, Tokyo
Weitere Informationen

Publikationsverlauf

Received:06. Dezember 1976

Publikationsdatum:
10. Januar 2018 (online)

Preview

Summary

Various renal imaging agents that were reported in the past and a new agent, 99mTc-malate as well as 99mTc-cystein acetazolamide complex were prepared using electrolysis and electrochemical methods. These were studied for their labelling efficiency. After animal experiments with selected 99mTc-com- pounds, 99mTc-rnalate proved to be sufficient for renal imaging with adequate concentration. 99mTcmalate differs from other renal imaging agents in the utilization of endogeneous metabolic product.

The first half time of 99mTc-malate in humans is 17 minutes, on the average, and the urinary excretion rate of 99mTc-malate is 36±6.05% in 1 hour after intravenous administration, 44 ± 3.41% in 2 hours and 50 + 5.62% in 3 hours.

In our 40 clinical experiences of 99m-Tc-rnalate, most cases demonstrated quite clear renal images in the serial scintiphotos except cases whose serum creatinines were over 4.5 mg/dl.